RecruitingPhase 2NCT06789913
A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation
Studying PIK3CA-related overgrowth syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Relay Therapeutics, Inc.
- Intervention
- RLY-2608(drug)
- Enrollment
- 277 enrolled
- Eligibility
- 2 years · All sexes
- Timeline
- 2025 – 2031
Study locations (25)
- Phoenix Children's Hospital, Phoenix, Arizona, United States
- Arkansas Children's Hospital, Little Rock, Arkansas, United States
- University of California, Los Angeles, Los Angeles, California, United States
- Stanford University, Palo Alto, California, United States
- University of California, San Francisco, San Francisco, California, United States
- Children's Hospital Colorado, Aurora, Colorado, United States
- Children's Hospital of Atlanta, Atlanta, Georgia, United States
- Riley Children's Hospital, Indianapolis, Indiana, United States
- Johns Hopkins Medical Institute, Baltimore, Maryland, United States
- Boston Children's Hospital, Boston, Massachusetts, United States
- Mayo Clinic, Rochester, Minnesota, United States
- Washington University School of Medicine, St Louis, Missouri, United States
- UNC Chapel Hill, Chapel Hill, North Carolina, United States
- Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
- Cleveland Clinic Children's, Cleveland, Ohio, United States
- +10 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06789913 on ClinicalTrials.govOther trials for PIK3CA-related overgrowth syndrome
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT06997588EPIK-P4: A Phase II Single-arm Study to Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum (PROS)Novartis Pharmaceuticals
- RECRUITINGNANCT06840015Use of Airpod Pros as Assistive TechnologyThe University of Texas at Dallas
- RECRUITINGNCT06956248Innovating Access to Novel Therapies Through Standardized Prospective Integration of Response Evaluations (IMPACT-INSPIRE)National Cancer Centre, Singapore
- RECRUITINGNCT06364579Patient Reported Outcomes (PROs) in Anal Cancer Patient Treated by Intensity Modulated Radiotherapy (IMRT).Fondazione Policlinico Universitario Agostino Gemelli IRCCS
- RECRUITINGPHASE1, PHASE2NCT06975618Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CYH33 in Patients With PIK3CA-related Overgrowth Spectrum (PROS) and PIK3CA-related Vascular Malformations (PRVM)Haihe Biopharma Co., Ltd.
- RECRUITINGNCT05898932Enhanced Clinical Decisions for Management of Benign Prostatic Hyperplasia Using Patient-Reported OutcomesNorthwestern University
- ACTIVE NOT RECRUITINGNCT05705947PROs Following Low-dose Irradiation for OsteoarthritisUniversity of North Carolina, Chapel Hill
- ACTIVE NOT RECRUITINGPHASE2NCT04980833Study Assessing Long-term Safety and Efficacy of Alpelisib in Patients With PIK3CA-Related Overgrowth Spectrum (PROS) Who Previously Participated in Study CBYL719F12002 (EPIK-P1)Novartis Pharmaceuticals